65
Participants
Start Date
September 23, 2021
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
ONO-7913
Specified dose on specified days
ONO-4538
Specified dose on specified days
Fluorouracil
Specified dose on specified days
Oxaliplatin
Specified dose on specified days
Levofolinate
Specified dose on specified days
Bevacizumab
Specified dose on specified days
Cetuximab
Specified dose on specified days
Fujita Health University Hospital, Toyoake
National Cancer Center Hospital East, Kashiwa
Hokkaido University Hospital, Sapporo
Kobe City Medical Center General Hospital, Kobe
St. Marianna University Hospital, Kawasaki
Kanagawa Cancer Center, Yokohama
Kurashiki Central Hospital, Kurashiki
Kansai Medical University Hospital, Hirakata
Osaka Medical and Pharmaceutical University Hospital, Takatsuki
Saitama Medical University International Medical Center, Hidaka
Saitama Cancer Center, Shinden
Cancer Institute Hospital of JFCR, Koto-Ku
National Cancer Center Hospital, Chūōku
Chiba Cancer Center, Chiba
National Hospital Organization Osaka National Hospital, Osaka
Osaka General Medical Center, Osaka
Osaka International Cancer Institute, Osaka
Lead Sponsor
Ono Pharmaceutical Co. Ltd
INDUSTRY